Medical specialties

MNA: Brigham and Women's Hospital Tells Nurses to Care for Patients Despite Living with COVID-19 Positive Family Members

Tuesday, November 24, 2020 - 4:43pm

"We have no closer contacts than our immediate family members," said Trish Powers, OR/Trauma RN and Chair of the MNA Bargaining Committee.

Key Points: 
  • "We have no closer contacts than our immediate family members," said Trish Powers, OR/Trauma RN and Chair of the MNA Bargaining Committee.
  • "It makes zero sense to send exposed nurses back into the hospital to care for patients.
  • Nurses can have COVID-19 without symptoms and spread it to their patients or colleagues and back out into the community."
  • The Brigham's inconsistent safety practices during the pandemic have made it even more risky to send nurses exposed to COVID-19 positive family members immediately back to the bedside.

The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019

Tuesday, November 24, 2020 - 4:30pm

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019.

Key Points: 
  • NEW YORK, Nov. 24, 2020 /PRNewswire/ -- The South & Central America cartilage degeneration market is expected to reach US$ 1,195.57 million by 2027 from US$ 959.32 million in 2019.
  • The cartilage degeneration market is growing primarily due to the increasing prevalence of sports injuries and obesity in South & Central America.
  • The growing prevalence of obesity is likely to accelerate the incidence of cartilage degeneration, which will drive the market growth.
  • A few of the major secondary sources associated with the South & Central America cartilage degeneration market report are the World Health Organization (WHO), and others.

iBiopsy®: Promising Results on a Preliminary Study to Identify the Severity of the Disease in Patients With Non-Alcoholic Steatohepatitis (NASH)

Tuesday, November 24, 2020 - 4:45pm

According to the World Health Organization (WHO), Non-Alcoholic Fatty Liver Disease (NAFLD) is a pandemic affecting 25% of the global population1.

Key Points: 
  • According to the World Health Organization (WHO), Non-Alcoholic Fatty Liver Disease (NAFLD) is a pandemic affecting 25% of the global population1.
  • For 20% of patients, NAFLD leads to a more severe disease, Non-Alcoholic Steatohepatitis (NASH).
  • Within the high-risk population of NASH patients, disease evolution can lead to cirrhosis and liver cancer.
  • In this clinical context, the objective of Medians preliminary retrospective study was to quantify the ability of iBiopsys learning algorithms to discriminate between early and advanced fibrosis grade in NASH patients.

Prominent Salt Lake City Plastic Surgeon Dr. Eric Cerrati Recognized by The Park Record as a 2020 People's Choice Top Plastic Surgeon

Tuesday, November 24, 2020 - 4:00pm

SALT LAKE CITY, Nov. 24, 2020 /PRNewswire-PRWeb/ --The Park City, Utah community recently voted for Dr. Eric Cerrati as one of the city's Best Plastic Surgeons in the local magazine's 2020 People's Choice edition.

Key Points: 
  • SALT LAKE CITY, Nov. 24, 2020 /PRNewswire-PRWeb/ --The Park City, Utah community recently voted for Dr. Eric Cerrati as one of the city's Best Plastic Surgeons in the local magazine's 2020 People's Choice edition.
  • Dr. Eric Cerrati is a double board-certified facial plastic surgeon and a well-respected authority in the field of cosmetic plastic and reconstructive surgery.
  • As a plastic surgeon who focuses on the face and neck, Dr. Cerrati uses the most advanced and cutting-edge techniques to provide long-lasting, elegant results.
  • If you would like to get more information about Dr. Eric Cerrati or his plastic surgery practice locations in Salt Lake City and South Jordan, Utah, please visit http://www.drericcerrati.com or call (801) 585-3223.

NeuroRx and Relief announce initial successful results from expanded access use of RLF-100™ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients

Tuesday, November 24, 2020 - 3:13pm

Only 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28.

Key Points: 
  • Only 17% of the control patients, all treated with best available intensive care unit (ICU) Standard of Care, survived to day 28.
  • The survival rate with RLF-100TM reported today is comparable to that seen among the open-label patients treated with RLF-100 by Youssef et al.
  • Despite advancements in treating COVID-19, survival for the patients at highest risk due to severe comorbidities has remained dismal in the absence of an effective therapy.
  • Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses.

Genmab Announces Enapotamab Vedotin Update

Tuesday, November 24, 2020 - 3:40pm

Copenhagen, Denmark; November 24, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin.

Key Points: 
  • Copenhagen, Denmark; November 24, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin.
  • While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers.
  • Enapotamab vedotin is fully owned by Genmab and the drug linker technology used for enapotamab vedotin was licensed from Seagen Inc.
    Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
  • Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody.

SCYNEXIS to Participate in Piper Sandler and Evercore ISI Conferences

Tuesday, November 24, 2020 - 2:34pm

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events .

Key Points: 
  • A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: https://www.scynexis.com/news-media/events .
  • SCYNEXIS, Inc.(NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to potentially help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant.
  • Our lead candidate,ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients.
  • The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

Exactech and Bodycad Sign Exclusive Distribution Agreement to Offer Personalized Unicompartmental Knee Replacement

Tuesday, November 24, 2020 - 2:30pm

Exactech , a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today the signing of an exclusive distribution agreement with orthopaedic manufacturer Bodycad for its Reflex Uni knee in the U.S.

Key Points: 
  • Exactech , a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today the signing of an exclusive distribution agreement with orthopaedic manufacturer Bodycad for its Reflex Uni knee in the U.S.
  • This new product offering expands Exactechs Truliant primary and revision knee system to include a personalized unicompartmental implant that is designed to fit each patients unique anatomy.
  • View the full release here: https://www.businesswire.com/news/home/20201124005330/en/
    Exactech introduces Truliant Reflex Uni by Bodycad, a personalized unicompartmental knee replacement.
  • The resulting patient-specific unicompartmental knee replacement requires no off-the-shelf implants and minimal instrumentation, making it ideally suited for an efficient hospital or ambulatory surgery center.

CF Foundation Awards Up to $3.3M to Polyphor for Inhaled Version of Antibiotic to Treat Pseudomonas

Tuesday, November 24, 2020 - 2:00pm

Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.

Key Points: 
  • Today, the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
  • An inhaled version could make it easier for someone with a Pseudomonas infection to take the drug from home.
  • In addition, the drug, which targets the outer membrane of bacteria, specifically focuses on Pseudomonas, which might have certain advantages over broad-spectrum antibiotics.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.

COVID-19 and ARDS Educational Webinar: Recovery and Life After the ICU

Tuesday, November 24, 2020 - 2:00pm

to discuss the connection between ARDS, COVID-19-induced ARDS, and post-ICU recovery:

Key Points: 
  • to discuss the connection between ARDS, COVID-19-induced ARDS, and post-ICU recovery:
    Eileen Rubin, J.D., Co-founder, President and CEO, founded the ARDS Foundation in 2000.
  • Dr. Michelle Biehl is the Medical Director for the Cleveland Clinic Post-ICU Recovery Clinic, a critical care physician and pulmonologist at the Cleveland Clinic.
  • ARDS Foundation is a nonprofit organization dedicated to supporting patients and families faced with the horrific diagnosis of Acute Respiratory Distress Syndrome (ARDS).
  • ARDS Foundation offers educational materials to families and patients, works passionately with clinicians, and partners with leaders in the industry to fight against ARDS together.